Trial record 1 of 1 for:
RIBOLARIS
Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer (RIBOLARIS)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05296746 |
|
Recruitment Status :
Recruiting
First Posted : March 25, 2022
Last Update Posted : October 10, 2023
|
Sponsor:
SOLTI Breast Cancer Research Group
Collaborators:
Novartis
UNICANCER
Information provided by (Responsible Party):
SOLTI Breast Cancer Research Group
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | August 1, 2028 |
| Estimated Study Completion Date : | July 1, 2030 |